Evidence map›Paper›PMID 40100743›Full record

ArticleJournal of Crohn's & colitis2025

Development and validation of a risk prediction tool for the diagnosis of inflammatory bowel disease in patients presenting in primary care with abdominal symptoms.

Nosheen Umar, Steven Wambua, Phil Harvey, Samuel Cusworth, Krish Nirantharakumar, Shamil Haroon, Nigel Trudgill, Nicola J Adderley

Abstract readValidation Study
In one paragraph

Article in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nosheen UmarDepartment of Gastroenterology, Sandwell and West Birmingham NHS Trust, West Bromwich, United Kingdom.ORCID 0000-0003-4312-2684
Steven WambuaInstitute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
Phil HarveyDepartment of Gastroenterology, New Cross Hospital, Wolverhampton, United Kingdom.ORCID 0000-0002-1192-9910
Samuel CusworthInstitute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
Krish NirantharakumarInstitute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-6816-1279
Shamil HaroonInstitute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
Nigel TrudgillDepartment of Gastroenterology, Sandwell and West Birmingham NHS Trust, West Bromwich, United Kingdom.
Nicola J AdderleyInstitute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0003-0543-3254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with inflammatory bowel disease (IBD) may experience delays in their diagnosis. This study aimed to develop and validate a risk prediction tool for IBD.

methodsA retrospective cohort study was conducted using primary care data from 2010 to 2019, including symptomatic patients aged ≥18. UK-based primary care databases linked to hospital records were utilized for model development and validation. Cox proportional hazards models were used to derive risk equations for IBD, ulcerative colitis (UC), and Crohn's disease (CD) in men and women. Candidate predictors included demographics, comorbidities, symptoms, extraintestinal manifestations, and laboratory results. Model performance was evaluated using measures of fit, discrimination, and calibration at 1, 2, 3, and 5 years after symptom onset.

resultsIn total, 2 054 530 patients were included in the derivation cohort and 673 320 in the validation cohort. In the derivation cohort, 0.7% were diagnosed with IBD (66.3% UC and 33.7% CD). Predictors in the final IBD model included age, smoking, body mass index, gastrointestinal symptoms, extraintestinal manifestations, comorbidities, family history of IBD, and laboratory investigations. The model demonstrated good discrimination and calibration; C-statistic 0.78 (95% confidence interval [CI], 0.77-0.79) in men and 0.78 (95% CI, 0.77-0.79) in women. In the validation cohort, the model tended to slightly overestimate IBD risk at higher risk thresholds.

conclusionsA risk model using patient demographics, symptoms, and laboratory results accurately predicted IBD, UC, and CD at 1, 2, 3, and 5 years after symptom onset, potentially aiding in prioritizing patients for a referral or fecal calprotectin testing in primary care.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesAbdominal PainAdultFemaleHumansMaleMiddle AgedPrimary Health CareProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsUnited KingdomCrohn’s diseasediagnosisinflammatory bowel diseaseprediction modelulcerative colitis

Identifiers

PMID40100743
PMCPMC12010163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.